Featured

Status

Health Topics

Any Category
Diseases
Hemic and Lymphatic Diseases
Clear Filters

Search Clinical Trials

65 Results
Withdrawn
H-36731: Finasteride in Management of Elevated Red Blood Cells
Hypogonadism is becoming an increasingly recognized clinical syndrome affecting millions of men in the United States and globally, and is characterized by symptoms including chronic fatigue, decreased libido and muscle …
Baylor Role: Lead Sponsor
Terminated
Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)
Patients will be recruited from the patient population followed at the Texas Children's Cancer and Hematology Centers (TCC/HC)/Baylor College of Medicine (BCM) and the University of Texas Houston Hematology Center. …
Baylor Role: Lead Sponsor
Completed
Home Away From Home - Medical Outcomes
This is a bidirectional observational cohort study. Participants will be patients less that 19 years of age at diagnosis receiving or having received chemotherapy for AML from seventeen participating pediatric …
Baylor Role: Collaborator
Completed
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
The standard of care in patients receiving rituximab is to give the dose slowly and gradually increase the rate of rituximab until the full dose is given, which may take …
Baylor Role: Lead Sponsor
Terminated
Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome
This pilot study investigates clinical benefit of four 28-day cycles of sertraline in low-risk MDS patients. Participants will receive 100mg of oral sertraline daily. The study will also evaluate potential …
Baylor Role: Collaborator
Recruiting
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
Up to 390 mL (78 teaspoons) of blood will be collected from the patient on one to three occasions over a two month period. Under certain conditions related to the …
Baylor Role: Lead Sponsor
Terminated
Treatment of Hemoglobin SC Disease With Hydroxyurea
To be eligible to participate in this study, patients must have HbSC disease, have experienced a sickle cell disease related complication, or have a score of 80 or lower on …
Baylor Role: Lead Sponsor
Recruiting
Sickle Cell Clinical Research and Intervention Program
The St. Jude Pediatric SCD Program has developed a comprehensive plan of care that spans the ages of 0 to 25, and provides the structure for screening and monitoring disease …
Baylor Role: Collaborator
Completed
Novel Dose Escalation to Predict Treatment With Hydroxyurea
To be eligible to participate in this study, patients must have decided that they want to begin hydroxyurea therapy. Patients choosing to participate in this study will be assigned randomly …
Baylor Role: Lead Sponsor
Recruiting
Natural History Study of GATA2 Deficiency and Related Disorders
Mutations in GATA2, a critical hematopoietic transcription factor, underlie a complex congenital disorder characterized by immunodeficiency, bone marrow failure, and lymphatic/vascular dysfunction. Patients with GATA2 deficiency may suffer from a …
Baylor Role: Collaborator